newsfilter
← Latest News
PR Newswire·

New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposureFindings build on first positive results where TREMFYA